0      0


JL1109EH - JL1109EH: Indirect treatment comparison (ITC) of momelotinib (MMB) vs fedratinib (FED) safety in patients (pts) with myelofibrosis (MF)


Full author listing

Authors: Lucia Masarova1, Srdan Verstovsek1, Francesca Palandri2, Ruben Mesa3, Claire Harrison4, Gautam Sajeev5, Boris Gorsh6, Ryan Simpson5, Sang Cho5, Zhaohui Wang6, Catherine Ellis6, Seán Conlon7, James Signorovitch5 

Affiliations: 1The University of Texas MD Anderson Cancer Center, Houston TX, USA; 2IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 3Wake Health, Winston-Salem, NC, USA; 4Guys and St Thomas’ NHS Foundation Trust, London, UK; 5Analysis Group, Boston, MA, USA; 6GSK plc, Philadelphia, PA, USA; 7GSK plc, Reading UK


Presenter(s):

You must be logged in and own this session in order to post comments.